HAMBURG & MUNICH, March 5, 2026
Daiichi Sankyo Europe and GAIA, a global pioneer in evidence-based digital therapeutics, have announced an exclusive strategic partnership to introduce lipodia, a next-generation digital therapeutic designed for adults with hypercholesterolemia. The collaboration aims to enhance cardiovascular care by combining pharmaceutical treatment with evidence-based behavioral therapy delivered through digital technology. Through this partnership, Daiichi Sankyo Europe secures exclusive commercialization rights to lipodia, initially targeting the German healthcare market with expansion plans for additional European countries. The initiative reflects a growing trend in healthcare innovation that integrates digital health solutions with traditional pharmacotherapy to improve long-term disease management and patient adherence.
Expanding Cardiovascular Care Beyond Medication
Hypercholesterolemia remains one of the most significant risk factors for atherosclerotic cardiovascular disease, as elevated low-density lipoprotein cholesterol (LDL-C) directly contributes to plaque formation in blood vessels and the development of heart attacks and strokes. Although effective pharmacological treatments are widely available, achieving and maintaining target LDL-C levels in real-world clinical practice continues to be challenging, largely due to inconsistent patient adherence and lifestyle factors. The introduction of lipodia aims to address this gap by supporting patients beyond traditional medication therapy, focusing on sustained behavioral change that improves long-term treatment outcomes.
The digital therapeutic operates as a fully automated behavioral support program, combining evidence-based methods from behavioral medicine, psychology, and psychotherapy. Through interactive digital dialogues and adaptive guidance, the application responds to individual patient needs and helps them develop healthier daily habits, strengthen treatment adherence, and maintain motivation over time. Designed for use on smartphones and other connected devices, lipodia enables flexible and location-independent access, making it easier for patients to incorporate health management into everyday life. By supporting medication adherence and lifestyle changes simultaneously, the program aims to improve long-term cholesterol control and cardiovascular risk reduction.
Strategic Partnership to Accelerate Digital Therapeutics
Advertisement
The collaboration brings together GAIA’s decades-long experience in clinically validated digital therapeutics and Daiichi Sankyo’s scientific leadership in cardiovascular disease prevention and treatment. Both organizations are members of the German Association of Research-Based Pharmaceutical Companies (vfa) and share a commitment to developing innovative, evidence-based healthcare solutions. The partnership reflects Daiichi Sankyo’s broader “beyond the pill” strategy, which focuses on delivering holistic care by integrating pharmaceuticals with digital and behavioral health tools.
Under the agreement, Daiichi Sankyo Europe will integrate lipodia into its cardiovascular portfolio, reinforcing its mission to improve patient outcomes through both therapeutic innovation and preventive care strategies. Cardiovascular diseases remain the leading cause of death in Europe, and experts estimate that a large proportion of heart disease and stroke cases could be prevented through improved lifestyle management and early intervention. By combining pharmacological expertise with digital behavioral support, the partners aim to close a longstanding gap in chronic care management and empower patients to play a more active role in managing their cardiovascular health.
Pathway Toward Reimbursement and Routine Care
To ensure broad accessibility, GAIA plans to submit lipodia for reimbursement under Germany’s Digital Health Applications (DiGA) framework once the pivotal Phase III randomized controlled trial data become available. If the application receives regulatory approval and reimbursement status, physicians will be able to prescribe the digital therapeutic as part of routine cardiovascular care, with coverage provided by statutory health insurance systems. This approach aims to reduce barriers to access while enabling patients to benefit from structured digital support in lipid management.
The DiGA pathway represents one of the most advanced regulatory frameworks for digital therapeutics globally, allowing clinically validated digital health solutions to be integrated into standard medical practice. The partnership between GAIA and Daiichi Sankyo Europe positions lipodia as a scalable digital health innovation capable of supporting millions of patients living with chronic cholesterol disorders. As digital therapeutics continue to gain recognition within the healthcare ecosystem, initiatives like this partnership demonstrate how technology-driven behavioral interventions can complement existing drug therapies and strengthen long-term disease prevention strategies.
By combining clinical science, behavioral psychology, and digital innovation, Daiichi Sankyo Europe and GAIA aim to reshape how hypercholesterolemia is managed in everyday healthcare settings, ultimately improving patient adherence, cardiovascular risk control, and long-term health outcomes.
z
Source: GAIA Digital Therapeutics, Daiichi Sankyo Europe press release
